Compare Novartis with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ALKEM LABORATORIES - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ALKEM LABORATORIES NOVARTIS/
ALKEM LABORATORIES
 
P/E (TTM) x 518.8 - - View Chart
P/BV x 29.1 7.0 414.5% View Chart
Dividend Yield % 1.5 0.6 245.9%  

Financials

 NOVARTIS   ALKEM LABORATORIES
EQUITY SHARE DATA
    NOVARTIS
Mar-19
ALKEM LABORATORIES
Mar-16
NOVARTIS/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs9801,589 61.7%   
Low Rs6001,232 48.7%   
Sales per share (Unadj.) Rs198.7417.5 47.6%  
Earnings per share (Unadj.) Rs21.056.3 37.2%  
Cash flow per share (Unadj.) Rs22.364.7 34.4%  
Dividends per share (Unadj.) Rs10.0012.70 78.7%  
Dividend yield (eoy) %1.30.9 140.6%  
Book value per share (Unadj.) Rs307.5292.9 105.0%  
Shares outstanding (eoy) m24.69119.57 20.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.03.4 117.7%   
Avg P/E ratio x37.725.1 150.4%  
P/CF ratio (eoy) x35.521.8 162.9%  
Price / Book Value ratio x2.64.8 53.4%  
Dividend payout %47.722.6 211.4%   
Avg Mkt Cap Rs m19,508168,653 11.6%   
No. of employees `0000.6NA-   
Total wages/salary Rs m1,1719,171 12.8%   
Avg. sales/employee Rs Th8,445.4NM-  
Avg. wages/employee Rs Th2,015.7NM-  
Avg. net profit/employee Rs Th891.0NM-  
INCOME DATA
Net Sales Rs m4,90749,915 9.8%  
Other income Rs m7831,645 47.6%   
Total revenues Rs m5,68951,561 11.0%   
Gross profit Rs m1238,482 1.4%  
Depreciation Rs m321,006 3.2%   
Interest Rs m16671 2.4%   
Profit before tax Rs m8588,451 10.1%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3401,606 21.2%   
Profit after tax Rs m5186,731 7.7%  
Gross profit margin %2.517.0 14.7%  
Effective tax rate %39.619.0 208.6%   
Net profit margin %10.613.5 78.2%  
BALANCE SHEET DATA
Current assets Rs m8,05527,062 29.8%   
Current liabilities Rs m1,85015,324 12.1%   
Net working cap to sales %126.423.5 537.7%  
Current ratio x4.41.8 246.5%  
Inventory Days Days4567 67.7%  
Debtors Days Days3441 82.2%  
Net fixed assets Rs m15012,610 1.2%   
Share capital Rs m123239 51.6%   
"Free" reserves Rs m7,46934,490 21.7%   
Net worth Rs m7,59235,027 21.7%   
Long term debt Rs m01,212 0.0%   
Total assets Rs m9,82454,387 18.1%  
Interest coverage x54.913.6 403.9%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.9 54.4%   
Return on assets %5.413.6 39.9%  
Return on equity %6.819.2 35.5%  
Return on capital %11.524.9 46.3%  
Exports to sales %012.9 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m586,563 0.9%   
Fx outflow Rs m1,3263,012 44.0%   
Net fx Rs m-1,2693,552 -35.7%   
CASH FLOW
From Operations Rs m-1,9437,259 -26.8%  
From Investments Rs m2,7421,864 147.1%  
From Financial Activity Rs m-298-9,273 3.2%  
Net Cashflow Rs m501-150 -334.2%  

Share Holding

Indian Promoters % 0.0 66.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 33.1 6.0%  
FIIs % 1.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 0.0 -  
Shareholders   41,647 68,381 60.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   DR. DATSONS LABS  DISHMAN PHARMA  TTK HEALTHCARE  ASTRAZENECA PHARMA  DIVIS LABORATORIES  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Nov 15, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS